Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31118151 | 1.00 | HCAR2 (0.46) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL9478482 | 0.98 | HCAR2 (0.45) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL69399 | 0.85 | KDM4E (0.55) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL27315955 | 0.79 | ALDH1A1 (0.34) | HCAR2KDM4ENAPRTTSHRALDH1A1 | |
| SCHEMBL14764682 | 0.79 | HCAR2 (0.45) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL163537 | 0.79 | ADORA3 (0.48) | HCAR2KDM4ENAPRTTSHRTDP1 | |
| SCHEMBL9478486 | 0.77 | CA1 (0.32) | HCAR2KDM4ENAPRTALDH1A1HPGD | |
| SCHEMBL162261 | 0.76 | HCAR2 (0.46) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL376147 | 0.74 | GRM5 (0.47) | HCAR2KDM4ENAPRTALOX15TSHR | |
| SCHEMBL3037984 | 0.74 | TSHR (0.54) | HCAR2KDM4ENAPRTALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0529653-B1 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1996-10-23 | — | — | EP | claimed |
| US-5238829-A | Hydroxylation of pyrazinecarboxylic acid(or salts) by Alcaligenes faecalis which can grow using picolinic acid(or salts) as sole source of carbon, nitrogen and energy | LONZA LTD. (CH) | 1993-08-24 | — | — | US | claimed |
| EP-0529653-A2 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1993-03-03 | — | — | EP | claimed |
| JP-5252968-A | — | — | None | — | — | JP | disclosed |
| JP-4304894-A | — | — | None | — | — | JP | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651954-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| EP-0529653-B1 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1996-10-23 | — | — | EP | disclosed |
| EP-0529653-B1 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1996-10-23 | — | — | EP | disclosed |
| JP-H05252968-A | MICROBIOLIGICAL PRODUCTION OF 6-HYDROXYPYRAZINECARBOXYLIC ACID | LONZA AG | 1993-10-05 | — | — | JP | disclosed |
| US-5238829-A | Hydroxylation of pyrazinecarboxylic acid(or salts) by Alcaligenes faecalis which can grow using picolinic acid(or salts) as sole source of carbon, nitrogen and energy | LONZA LTD. (CH) | 1993-08-24 | — | — | US | disclosed |
| US-5238829-A | Hydroxylation of pyrazinecarboxylic acid(or salts) by Alcaligenes faecalis which can grow using picolinic acid(or salts) as sole source of carbon, nitrogen and energy | LONZA LTD. (CH) | 1993-08-24 | — | — | US | disclosed |
| EP-0529653-A2 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1993-03-03 | — | — | EP | disclosed |
| EP-0529653-A2 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1993-03-03 | — | — | EP | disclosed |
| EP-0529653-A2 | Microbiological process for the preparation of 6-hydroxy pyrazinoic acid | LONZA AG (CH) | 1993-03-03 | — | — | EP | disclosed |
| JP-H04304894-A | PRODUCTION OF HYDROXIDE OF PICOLINIC ACID OR PYRAZINIC ACID BY MICROORGANISM | IKEDA SHIYOKUKEN KK | 1992-10-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | HCAR2 1506/4885KDM4E 2432/4885NAPRT 1354/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | HCAR2 1506/4885KDM4E 2432/4885NAPRT 1354/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | HCAR2 713/4885KDM4E 3133/4885NAPRT 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.